Cited by 1,086SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesRespiratory viral infections research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Open access

Gupta, Anil, Gonzalez-Rojas, Yaneicy, Juarez, Erick, Crespo Casal, Manuel, Moya, Jaynier, Falci, Diego R., Sarkis, Elias, Solis, Joel, Zheng, Hanzhe, Scott, Nicola, Cathcart, Andrea L., Hebner, Christy M., Sager, Jennifer, Mogalian, Erik, Tipple, Craig, Peppercorn, Amanda, Alexander, Elizabeth, Pang, Phillip S., Free, Almena, Brinson, Cynthia, Aldinger, Melissa, Shapiro, Adrienne E.·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2107934

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS: In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a dose of 500 mg or placebo. The primary efficacy outcome was hospitalization (for >24 hours) for any cause or death within 29 days after randomization. RESULTS: In this prespecified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, had disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; P = 0.002). In the placebo group, 5 patients were admitted to the intensive care unit, including 1 who died by day 29. Safety was assessed in 868 patients (430 in the sotrovimab group and 438 in the placebo group). Adverse events were reported by 17% of the patients in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively). CONCLUSIONS: Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified. (Funded by Vir Biotechnology and GlaxoSmithKline; COMET-ICE ClinicalTrials.gov number, NCT04545060.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa2107934

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., François, F., & Horwitz, L. I. (2020) · BMJ · doi:10.1136/bmj.m1966 · Cited by 3,045
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S. R., Boundy, E. O., Bowen, V. B., Chow, N. A., Cohn, A. C., Dowling, N. F., Ellington, S., Gierke, R., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e2 · Cited by 2,278
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19
Liang, W., Liang, H., Ou, L., Chen, B., Chen, A., Li, C., Li, Y., Guan, W., Sang, L., Lu, J., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.2033 · Cited by 1,387
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881

Flagged first, then by citations

Show all 25 references

Sorted by citations

Items 401–500 of 1,000

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness
Plotnik, D. A., Sager, J. E., Aryal, M., Fanget, M. C., Peter, A., Schmid, M., Cebrik, D., Mogalian, E., Boundy, K., Yeh, W. W., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01273-23 · Cited by 10
Self-citation
Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2
Yu, P., Ran, J., Yang, R., Zhu, H., Song, L., Wu, Y., Zhao, T., & Xiong, T.-C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1374913 · Cited by 11
External validation of the COVID-19 4C mortality score in an urban United States cohort
Riley, J. M., Moeller, P. J., Crawford, A. G., Schaefer, J. W., Cheney-Peters, D. R., Venkataraman, C. M., Li, C. J., Smaltz, C. M., Bradley, C. G., Lee, C. Y., et al. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2022.04.030 · Cited by 10
Outpatient treatment options to address the SARS-CoV-2 variant Omicron
McCarthy, M. W. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2077191 · Cited by 10
Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
Totschnig, D., Doberer, D., Haberl, R., Wenisch, C., & Valipour, A. (2022) · IDCases · doi:10.1016/j.idcr.2022.e01528 · Cited by 10
Lessons from SARS‑CoV‑2 and its variants (Review)
Qin, Z., Sun, Y., Zhang, J., Zhou, L., Chen, Y., & Huang, C. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12779 · Cited by 10
Curbing the Delta Surge
Razonable, R. R., O’Horo, J. C., Challener, D. W., Arndt, L. L., Arndt, R. F., Clune, C. G., Culbertson, T. L., Hall, S. T., Heyliger, A., Jackson, T. A., et al. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.06.015 · Cited by 10
Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents
Choi, S., Choi, J. H., & Yun, K. W. (2022) · Korean Journal of Pediatrics · doi:10.3345/cep.2022.00458 · Cited by 10
Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab
Ballotta, L., Simonetti, O., D’Agaro, P., Segat, L., Koncan, R., Martínez-Orellana, P., Dattola, F., Orsini, E., Marcello, A., Monego, S. D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.945060 · Cited by 10
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study
Prins, M. L. M., van der Plas, J. L., Vissers, M. F. J. M., Berends, C. L., Tresch, G., Soergel, M., Fernández, E., van den Berge, N., Duijsings, D., Zitt, C., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15560 · Cited by 10
Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID ‐19
Sager, J. E., El‐Zailik, A., Passarell, J. A., Roepcke, S., Li, X., Aldinger, M., Nader, A., Skingsley, A., Alexander, E. L., Yeh, W. W., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12958 · Cited by 10
Self-citation
Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages
Ren, P., Hu, Y., Peng, L., Yang, L., Suzuki, K., Fang, Z., Bai, M., Zhou, L., Feng, Y., Zou, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01509-1 · Cited by 10
Neonatal urinary tract infection: clinical response to empirical therapy versus in vitro susceptibility at Bahrami Children's Hospital- Neonatal Ward: 2001-2010.
Taheri, P. A., Navabi, B., & Shariat, M. (2012) · PubMed · Cited by 10
Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients on kidney replacement therapy: observational cohort study using the OpenSAFELY-UKRR linked platform and SRR databasePreprint
Collaborative, T. O., Zheng, B., Campbell, J., Carr, E. J., Tazare, J., Nab, L., Mahalingasivam, V., Mehrkar, A., Santhakumaran, S., Steenkamp, R. D., et al. (2022) · medRxiv · doi:10.1101/2022.12.02.22283049 · Cited by 10
Early 3-day course of remdesivir in vaccinated outpatients with SARS-CoV-2 infection. A success story
Panagopoulos, P., Petrakis, V., Trypsianis, G. A., & Papazoglou, D. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2099693 · Cited by 9
COVID-19: An Update on the Latest Therapeutic Agents
Loo, K.-Y., Tan, L. T., Law, J. W., Hong, K., Chan, K., & Letchumanan, V. (2023) · Progress In Microbes & Molecular Biology · doi:10.36877/pmmb.0000329 · Cited by 9
A protective and broadly binding antibody class engages the influenza virus hemagglutinin head at its stem interface
Simmons, H. C., Finney, J., Kotaki, R., Adachi, Y., Moseman, A. P., Watanabe, A., Song, S., Robinson‐McCarthy, L. R., Sage, V. L., Kuraoka, M., et al. (2025) · mBio · doi:10.1128/mbio.00892-25 · Cited by 11
Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study
Choi, S. J., Park, S., & Lee, E. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2021.0140 · Cited by 9
Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis
Scholl, A. R., Korentzelos, D. K., Forns, T., Brenneman, E. K., Kelm, M. J., Datto, M., Wheeler, S., & Carlsen, E. D. (2022) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfac064 · Cited by 9
Experience with sotrovimab treatment of SARS‐CoV‐2‐infected patients in Denmark
Rasmussen, L. D., Lebech, A., Øvrehus, A. L. H., Poulsen, B. K., Christensen, H. R., Nielsen, H. I., Johansen, I. S., Omland, L. H., Wiese, L., Helleberg, M., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15644 · Cited by 10
Insight into free energy and dynamic cross-correlations of residue for binding affinity of antibody and receptor binding domain SARS-CoV-2
Chong, W. L., Saparpakorn, P., Sangma, C., Lee, V. S., & Hannongbua, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2022.e12667 · Cited by 9
Inhibition of Rab1B Impairs Trafficking and Maturation of SARS-CoV-2 Spike Protein
Veeck, C., Biedenkopf, N., Rohde, C., Becker, S., & Halwe, S. (2023) · Viruses · doi:10.3390/v15040824 · Cited by 9
COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants
Padasas, B. T., Españo, E., Kim, S., Song, Y., Lee, C., & Kim, J.-K. (2023) · Immune Network · doi:10.4110/in.2023.23.e13 · Cited by 9
Isolation and characterization of single domain antibodies from banded houndshark (Triakis scyllium) targeting SARS-CoV-2 spike RBD protein
Kim, W. S., Chae, H. D., Jung, I., Lee, W., Lee, W. J., Lee, J., Gong, Y., Lee, D., Kim, B.-W., Kim, J.-K., et al. (2023) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2023.108807 · Cited by 9
Viral dynamics of SARS-CoV-2 in immunocompromised patients
Utzon, A. N., Johansen, I. S., Bang, L. L., Pedersen, R. M., Andersen, T. E., & Madsen, L. W. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.05.013 · Cited by 9
Tocilizumab versus anakinra in COVID-19: results from propensity score matching
Arcani, R., Corréard, F., Suchon, P., Kaplanski, G., Jean, R., Cauchois, R., Leprince, M., Arcani, V., Seguier, J., Marie, B. D. S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1185716 · Cited by 9
Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan
Hirai, J., Mori, N., Sakanashi, D., Ohashi, W., Shibata, Y., Asai, N., Kato, H., Hagihara, M., & Mikamo, H. (2023) · Viruses · doi:10.3390/v15091952 · Cited by 9
Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review
Madi, K., Flumian, C., Olivier, P., Sommet, A., & Montastruc, F. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000352 · Cited by 10
Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials
Zyoud, S. H. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01254-3 · Cited by 9
Development of a colorimetric assay for the detection of SARS-CoV-2 3CLpro activity
Garland, G. D., Harvey, R. F., Mulroney, T. E., Monti, M., Fuller, S., Haigh, R., Gerber, P. P., Barer, M. R., Matheson, N. J., & Willis, A. E. (2022) · Biochemical Journal · doi:10.1042/bcj20220105 · Cited by 9
COVID-19-Current Therapeutical Approaches and Future Perspectives
Moisi, R. E., Nedea, M. I., Velescu, B. Ș., Udeanu, D. I., Sultana, C., Ruță, S. M., & Arsene, A. L. (2022) · Processes · doi:10.3390/pr10061053 · Cited by 9
Simplified Lung Ultrasound Examination and Telehealth Feasibility in Early SARS-CoV-2 Infection
Kimura, B. J., Resnikoff, P. M., Tran, E. M., Bonagiri, P. R., & Bagsic, S. R. S. (2022) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2022.05.015 · Cited by 9
Efficacy of COVID-19 treatments among geriatric patients: a systematic review
Senderovich, H., Vinoraj, D., Stever, M., & Waicus, S. (2022) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361221095666 · Cited by 9
Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study
Cimellaro, A., Addesi, D., Cavallo, M., Spagnolo, F., Suraci, E., Cordaro, R., Spinelli, I., Passafaro, F., Colosimo, M., Pintaudi, M., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10123135 · Cited by 9
COVID-19, Law & Regulation
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · doi:10.1093/oso/9780192896742.001.0001 · Cited by 9
Diabetes mellitus is associated with 90-day mortality in old critically ill COVID-19 patients: a multicenter prospective observational cohort study
Mayerhöfer, T., Klein, S., Wernly, B., Flaatten, H. K., Guidet, B., de Lange, D. W., Fjølner, J., Leaver, S. K., Beil, M., Sviri, S., et al. (2023) · Infection · doi:10.1007/s15010-023-02001-2 · Cited by 9
PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V)
Humphrey, T. J. L., Dosanjh, D. P. S., Hiemstra, T. F., Richter, A. G., Chen-Xu, M., Qian, W., Jha, V., Gatley, K., Adhikari, R., Dowling, F., et al. (2023) · Trials · doi:10.1186/s13063-023-07128-z · Cited by 9
19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern
García‐Vega, M., Melgoza-González, E. A., Hernández‐Valenzuela, S., Hinojosa‐Trujillo, D., Reséndiz‐Sandoval, M., Llamas-Covarrubias, M. A., Loza-López, M., Valenzuela, O., Soto‐Gaxiola, A., Hernández‐Oñate, M. Á., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106562 · Cited by 9
Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 accelerates SARS‐CoV‐2 clearance: A single‐center propensity score‐matched cohort study
Song, R., Chen, X., Li, B., Zhang, H., Guo, X., Liu, Z., Zou, L., Xiao, L., Lei, C., Mao, F., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28805 · Cited by 10
Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern
Cohen‐Dvashi, H., Weinstein, J. J., Katz, M., Eilon-Ashkenazy, M., Mor, Y., Shimon, A., Achdout, H., Tamir, H., Israely, T., Strobelt, R., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105193 · Cited by 9
Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages: emulated target trials using the OpenSAFELY platformPreprint
collaborative, T. O., Tazare, J., Nab, L., Zheng, B., Hulme, W. J., Green, A. C. A., Curtis, H. J., Mahalingasivam, V., Higgins, R., Schultze, A., et al. (2023) · medRxiv · doi:10.1101/2023.05.12.23289914 · Cited by 9
Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study
Woo, M. S., Brehm, T. T., Fischer, M., Heyer, A., Wichmann, D., Jordan, S., Nörz, D. S., Lütgehetmann, M., Addo, M. M., Lohse, A. W., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.04103-22 · Cited by 8
The Scope and Impact of Viral Infections in Common Variable Immunodeficiency (CVID) and CVID-like Disorders: A Literature Review
Al‐Hakim, A., Kačar, M., & Savic, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061717 · Cited by 9
Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies
Wirchnianski, A. S., Nyakatura, E. K., Herbert, A. S., Kuehne, A. I., Abbasi, S. A., Florez, C., Storm, N., McKay, L. G. A., Dailey, L., Kuang, E. A., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012134 · Cited by 8
Inhalable dry powders of a monoclonal antibody against SARS-CoV-2 virus made by thin-film freeze-drying
Xu, H., Sahakijpijarn, S., Moon, C., Emig, C. J., Mena, M. A., Henry, S. J., Vitug, A. A., Ventura, C. J., Kuehl, P. J., Revelli, D., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124511 · Cited by 8
Broad-spectrum coronavirus vaccines: integrated strategies to combat viral diversity
He, Q., Zhang, Y., Fu, Z., Ma, X., & Liang, Z. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2538561 · Cited by 8
Development of a potent monoclonal antibody for treatment of human metapneumovirus infections
Harris, E. D., McGovern, M., Pernikoff, S., Ikeda, R., Kipnis, L., Hannon, W. W., Sobolik, E. B., Gray, M. D., Greninger, A. L., He, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69328-w · Cited by 8
Passive immune therapies: another tool against COVID-19
Estcourt, L. J. (2021) · Hematology · doi:10.1182/hematology.2021000299 · Cited by 8
COVID-19 associated coagulopathy and thrombosis in cancer
Levi, M. M., & van Es, N. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2021.12.006 · Cited by 8
An outlook on potential protein targets of COVID-19 as a druggable site
Noori, R., & Sardar, M. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07724-3 · Cited by 9
Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis
Farhadian, N., Farhadian, M., Zamanian, M. H., Taghadosi, M., & Vaziri, S. (2022) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2022.2160733 · Cited by 8
Mechanism of a rabbit monoclonal antibody broadly neutralizing SARS-CoV-2 variants
Guo, H., Yang, Y., Zhao, T., Lu, Y., Gao, Y., Li, T., Xiao, H., Chu, X., Zheng, L., Li, W., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04759-5 · Cited by 9
Wearable and Invisible Sensor Design for Eye-Motion Monitoring Based on Ferrofluid and Electromagnetic Sensing Technologies
Tang, J., Luk, P. C. K., & Zhou, Y. (2023) · Bioengineering · doi:10.3390/bioengineering10050514 · Cited by 8
Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents
Wang, Z., Li, D., Chen, Y., Sun, Y., Jin, C., Hu, C., Feng, Y., Su, J., Ren, L., Hao, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160283 · Cited by 8
Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
Gonzalez-Bocco, I. H., Beluch, K., Cho, A., Lahoud, C., Reyes, F. A., Moshovitis, D. G., Unger-Mochrie, G. M., Wang, W., Hammond, S. P., Manne‐Goehler, J., et al. (2023) · Pilot and Feasibility Studies · doi:10.1186/s40814-023-01325-y · Cited by 8
What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study
VITO, A. D., Colpani, A., Poliseno, M., Diella, L., Ieva, F. R. P., Belati, A., Papale, R., Babudieri, S., Santis, L. D., Saracino, A., et al. (2023) · Viruses · doi:10.3390/v15081757 · Cited by 8
Mortality and clinical outcomes following SARS‐CoV ‐2 infection among individuals with haematological malignancies: A Danish population‐based cohort study
Lund, L. C., Rahbek, M. T., Brown, P. D. N., Obel, N., Hallas, J., & Frederiksen, H. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14108 · Cited by 8
Multiple sclerosis and COVID-19: interactions and unresolved issues
Zabalza, A., Thompson, A. J., Rotstein, D., Bar‐Or, A., & Montalbán, X. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00006-7 · Cited by 8
Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor
Treewattanawong, W., Sitthiyotha, T., & Chunsrivirot, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-00684-x · Cited by 8
Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects
Nawab, D. H. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1985891 · Cited by 9
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies
Cao, X., Maruyama, J., Zhou, H., Fu, Y., Kerwin, L., Powers, C., Sattler, R. A., Manning, J. T., Singh, A., Lim, R. K. V., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19780-7 · Cited by 8
Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt?
Mariniello, D. F., Allocca, V., D’Agnano, V., Villaro, R., Lanata, L., Bagnasco, M., Aronne, L., Bianco, A., & Perrotta, F. (2022) · Molecules · doi:10.3390/molecules27248919 · Cited by 9
The ‘myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19’ is far from reality
Dhibar, D. P., Arora, N., Chaudhary, D., Prakash, A., Medhi, B., Singla, N., Mohindra, R., Suri, V., Bhalla, A., Sharma, N., et al. (2023) · Scientific Reports · doi:10.1038/s41598-022-26053-w · Cited by 8
Cancer, more than a “COVID-19 co-morbidity”
Jani, C., Schooley, R. T., McKay, R. R., & Lippman, S. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1107384 · Cited by 9
Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19
Sun, J., Yang, Z.-D., Xie, X., Li, L., Zeng, H., Gong, B., Xu, J., Wu, J., Qu, B.-B., & Song, G. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i10.2168 · Cited by 8
Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
Kauer, V., Totschnig, D., Waldenberger, F. R., Augustin, M., Karolyi, M., Naegeli, M., Wenisch, C., & Zoufaly, A. (2023) · Viruses · doi:10.3390/v15051181 · Cited by 8
Transfusion reactions associated with COVID ‐19 convalescent plasma in outpatient clinical trials
Huaman, M. A., Raval, J. S., Paxton, J. H., Mosnaim, G. S., Patel, B., Anjan, S., Meisenberg, B. R., Levine, A. C., Marshall, C. E., Yarava, A., et al. (2023) · Transfusion · doi:10.1111/trf.17485 · Cited by 8
Ofeleein i mi Vlaptin—Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic
Kountouras, J., Gialamprinou, D., Kotronis, G., Papaefthymiou, A., Economidou, E. C., Soteriades, E. S., Vardaka, E., Chatzopoulos, D., Tzitiridou‐Chatzopoulou, M., Papazoglou, D. D., et al. (2022) · Medicina · doi:10.3390/medicina58020309 · Cited by 8
Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19
Mazzotta, V., Cozzi‐Lepri, A., Colavita, F., Lanini, S., Rosati, S., Lalle, E., Mastrorosa, I., Cimaglia, C., Vergori, A., Bevilacqua, N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.868020 · Cited by 8
Biologics in COVID-19 So Far: Systematic Review
Arias, M., Oliveros, H., Lechtig, S., & Bustos, R. (2022) · Pharmaceuticals · doi:10.3390/ph15070783 · Cited by 9
Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19
Jalbert, J. J., Hussein, M. A., Mastey, V., Sanchez, R. J., Wang, D., Murdock, D. J., Farinas, L., Bussey, J., Duart, C., Hirshberg, B., et al. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00691-z · Cited by 8
COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma
Sullivan, D. J., & Casadevall, A. (2023) · mBio · doi:10.1128/mbio.00428-23 · Cited by 8
A systems biology approach to define SARS-CoV-2 correlates of protection
Brady, C., Tipton, T., Carnell, O. T., Longet, S., Gooch, K. E., Hall, Y., Salguero, J., Tomić, A., & Carroll, M. W. (2025) · npj Vaccines · doi:10.1038/s41541-025-01103-2 · Cited by 7
Characterization of pathogen‐inactivated COVID ‐19 convalescent plasma and responses in transfused patients
Weisser, M., Khanna, N., Hedstueck, A., Tschudin‐Sutter, S., Roesch, S., Stehle, G., Sava, M., Deigendesch, N., Battegay, M., Infanti, L., et al. (2022) · Transfusion · doi:10.1111/trf.17083 · Cited by 7
Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
Papadimitriou‐Olivgeris, M., Cipriano, A. S., Guggisberg, N., Kroemer, M., Tschopp, J., Manuel, O., & Golshayan, D. (2022) · Transplant International · doi:10.3389/ti.2022.10721 · Cited by 7
Demographics and Outcomes of Initial Phase of COVID-19 Medicines Delivery Units Across 4 UK Centers During Peak B1.1.529 Omicron Epidemic: A Service Evaluation
Brown, M., Saund, J., Qureshi, A., Plowright, M., Drury, K., Gahir, J., Simpson, T., Newman, T., Adams, K., Galloway, J. B., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac527 · Cited by 7
Neutralization escape of emerging subvariants XBB.1.5/1.9.1 and XBB.2.3 from current therapeutic monoclonal antibodies
Chye, D. H., Chew, C. W. Y., Yeo, H. P., Tambyah, P. A., Young, B. E., Tan, G. G. Y., Tan, B. H., Vasoo, S. S., & Chan, C. E. Z. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29074 · Cited by 7
Respiratory syncytial virus–approved mAb Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors
Ettich, J., Wittich, C., Moll, J. M., Behnke, K., Floss, D. M., Reiners, J., Christmann, A., Lang, P. A., Smits, S. H. J., Kolmar, H., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105270 · Cited by 7
A Scalar Approach to Vaccination Ethics
Kraaijeveld, S. R., Gur‐Arie, R., & Jamrozik, E. (2023) · The Journal of Ethics · doi:10.1007/s10892-023-09445-6 · Cited by 7
Tracking antigen‐specific TCR clonotypes in SARS‐CoV‐2 infection reveals distinct severity trajectories
Kim, I. S., Kang, C. K., Lee, S. J., Lee, C., Kim, M., Seo, C., Kim, G., Lee, S., Park, K. S., Chang, E., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29199 · Cited by 8
Resistance Analysis Following Sotrovimab Treatment in Participants with COVID-19 During the Phase III COMET-ICE Study
Subramanian, S., Schnell, G., di Iulio, J., Gupta, A. K., Shapiro, A. E., Sarkis, E. H., Lopuski, A., Peppercorn, A., Aldinger, M., Hebner, C. M., et al. (2023) · Future Virology · doi:10.2217/fvl-2023-0146 · Cited by 7
Self-citation
Real‐Life Comparison of Antivirals for SARS‐CoV‐2 Omicron Infection in Patients With Hematologic Malignancies
Aiello, T. F., Peyrony, O., Chumbita, M., Monzó, P., Lopera, C., Puerta‐Alcalde, P., Magnano, L., Fernández‐Avilés, F., Cuesta, G., Tuset, M., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13264 · Cited by 7
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2
Choudhary, M. C., Deo, R., Evering, T. H., Chew, K. W., Giganti, M. J., Moser, C., Ritz, J., Regan, J., Flynn, J. P., Crain, C. R., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae192 · Cited by 7
Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitro IC50 values predict SARS‐CoV‐2 neutralising antibody titres
Clegg, L. E., Stepanov, O., Matthews, S., White, T., Seegobin, S., Thomas, S., Tuffy, K. M., Någård, M. B., Esser, M. T., Streicher, K. L., et al. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.1517 · Cited by 7
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19
Casadevall, A., McConnell, S. A., & Focosi, D. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2388186 · Cited by 7
Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis
Kumar, P., Zhang, X., Shaha, R., Kschischo, M., & Dobbelstein, M. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.106006 · Cited by 7
Phylogenetic meta-analysis of persistent SARS-CoV-2 infections in immunocompromised individuals highlights the challenges of robust evolutionary rate estimation caused by low genetic diversity
Översti, S., Gaul, E., Jensen, B. O., & Kühnert, D. (2025) · Virus Evolution · doi:10.1093/ve/veaf065 · Cited by 7
Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?
Golnabi, E. Y., Sanders, J. M., Johns, M. L., Lin, K., Ortwine, J. K., Wei, W., Mang, N. S., & Cutrell, J. B. (2021) · Current Infectious Disease Reports · doi:10.1007/s11908-021-00769-8 · Cited by 7
Clonal Wars: Monoclonal Antibodies Against Infectious Pathogens
Tan, J. (2021) · DNA and Cell Biology · doi:10.1089/dna.2021.0457 · Cited by 7
Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients
Trümpelmann, S., Schulte‐Mecklenbeck, A., Steinberg, O. V., Wirth, T., Fobker, M., Lohmann, L., Lünemann, J. D., Wiendl, H., Groß, C. C., & Klotz, L. (2022) · Clinical and Translational Science · doi:10.1111/cts.13256 · Cited by 7
Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern
Kondo, T., Matsuoka, K., Umemoto, S., Fujino, T., Hayashi, G., Iwatani, Y., & Murakami, H. (2022) · Life Science Alliance · doi:10.26508/lsa.202101322 · Cited by 7
Применение КОВИД-глобулина в терапии COVID-19
Арутюнов, А. Г., Avdeev, S. N., Батюшин, М. М., Boyarkov, A. V., Буланов, А. Ю., Bykova, E. A., Радикович, Г. Г., Nikitin, I. G., Панкратова, А. А., Razumikhin, M., et al. (2022) · Экспериментальная и клиническая фармакология · doi:10.30906/0869-2092-2022-85-3-13-20 · Cited by 7
Treatment strategies of COVID-19: A rheumatology perspective
Drosos, A. A., Pelechas, E., & Voulgari, P. V. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.05.014 · Cited by 7
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants
Brehm, T. T., Pfefferle, S., von Possel, R., Karolyi, M., Zoufaly, A., Wichmann, D., Kobbe, R., Emmerich, P., Nörz, D. S., Aepfelbacher, M., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27916 · Cited by 7
VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
Kulemzin, S. V., Sergeeva, M. V., Baranov, K. O., Gorchakov, A. A., Guselnikov, S. V., Николаевна, Б. Т., Volkova, O. Y., Najakshin, A. M., Chikaev, N. A., Danilenko, D., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060895 · Cited by 7
Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era
Izumo, T., Awano, N., Kuse, N., Sakamoto, K., Takada, K., Muto, Y., Fujimoto, K., Saiki, A., Ito, Y., Ota, H., et al. (2022) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2022.01036 · Cited by 7
Comparative outcomes after early Sotrovimab administration in vaccinated and unvaccinated kidney transplant recipients with SARS‐CoV‐2 infection during the Delta and Omicron BA.1 surges
Vathsala, A., Somani, J., D’Costa, M. R., Lum, L. H.-W., Wong, E. T. Y., & Sran, H. K. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13930 · Cited by 7
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Seo, J.-M., Kang, B., Song, R., Noh, H., Kim, C., Kim, J.-I., Kim, M., Ryu, D.-K., Lee, M., Yang, J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2117094 · Cited by 7
Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics
Battaglini, D., Cruz, F. F., Robba, C., Pelosi, P. P., & Rocco, P. R. M. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2120801 · Cited by 7
Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients
Yetmar, Z. A., Bhaimia, E., & Razonable, R. R. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000981 · Cited by 7

Authors: Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., Cathcart, A. L., Hebner, C. M., Sager, J., Mogalian, E., Tipple, C., Peppercorn, A., Alexander, E., Pang, P. S., Free, A., Brinson, C., Aldinger, M., & Shapiro, A. E.
Affiliations: William Osler Health System (CA)
From the Albion Finch Medical Centre, William Osler Health Centre, Toronto (A.G.); Optimus U (Y.G.-R.) and Florida International Medical Research (E.J.), Miami, Pines Care Research Center, Pembroke Pines (J.M.), and Sarkis Clinical Trials, Gainesville (E.S.) — all in Florida; Álvaro Cunqueiro Hospital, IIS Galicia Sur, Vigo, Spain (M.C.C.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (D.R.F.); Centex Studies, McAllen (J. Solis), and Central Texas Clinical Research, Austin (C.B.) — both in Texas; Vir Biotechnology, San Francisco (H.Z., A.L.C., C.M.H., J. Sager, E.M., E.A., P.S.P., M.A.); GlaxoSmithKline, Stevenage, United Kingdom (N.S., C.T.); GlaxoSmithKline, Cambridge, MA (A.P.); Pinnacle Research Group, Anniston, AL (A.F.); and the Departments of Global Health and Medicine, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle (A.E.S.).
Hospital de Clínicas de Porto Alegre (BR)
The University of Texas at Austin (US)
VIR Biotechnology (United States) (US)
GlaxoSmithKline (United Kingdom) (GB)
GlaxoSmithKline (United States) (US)
University of Washington (US)
Corresponding author: Shapiro, Adrienne E.
ORCID: Pang, Phillip S.
Shapiro, Adrienne E.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-11-18
Volume: 385
Issue: 21
Pages: 1941-1950
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2107934
OpenAlex: W3208080692
Cited by: 1,086
References: 25
Citations by year: 2026: 25 · 2025: 72 · 2024: 119 · 2023: 294 · 2022: 509 · 2021: 62
FWCI: 78.13
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by-nc-nd
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: sotrovimab, COVID-19 pandemic, SARS-CoV-2, neutralizing monoclonal antibodies, early treatment, disease progression, hospitalization, mortality, high-risk patients, non-hospitalized patients, presymptomatic treatment, adverse events
MeSH terms: SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Ambulatory Care, Double-Blind Method, Female, Hospitalization, Humans, Infusions, Intravenous, Length of Stay, Male, Middle Aged, Incidence, Disease Progression, Antibodies, Neutralizing, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks